ΔΎΉΟΦ±²₯

Meeting Coverage

SITC

Society for Immunotherapy of Cancer

Melanoma Resistant to Anti-PD-1 Responds to Tumor Infiltrating Lymphocytes

Almost a third of patients had objective responses, which deepened over time, study showed

SITC over a photo of the Boston Convention and Exhibition Center in Boston, Massachusetts.

Latest SITC Meeting Coverage

Allogeneic CAR T-Cell Therapy Shows Early Promise in Kidney Cancer

CTX130 yields sustained complete response in one patient with relapsed/refractory disease

November 15, 2022
Mixed Results With Fecal Transplant to Stimulate Cancer Immunotherapy Response

Encouraging activity with antibiotic-free protocol but not with vancomycin preconditioning

November 14, 2022
IL-8 Antibody Active in Tumors After PD-1/L1 Blockade

Clinical benefit in more than a third of patients with anti-IL-8/nivolumab combo

November 13, 2020
PD-1 Inhibitor Active in Progressive Basal Cell Cancer

Response rate of 20-30% with cemiplimab after post-hedgehog inhibitor progression or intolerance

November 11, 2020

Latest Oncology/Hematology Meeting Coverage